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transplanting B6 BM-TCD into BALB/c Rag1/ or into BALB/
c B6 F1 recipients, co-transplanting B6 T-regs again augmented
donor colonies (Rag1/, p  .001; F1, p  .01). Notably, co-
transplantation of B6 T-regs increased the already elevated pro-
genitor colony numbers detected in the absence of NK resistance
following transplant of BALB/c  B6 F1 BM-TCD into BALB/c
recipients (p  .001). Finally, when allogeneic antigen, T-cell
resistance, and NK resistance were simultaneously eliminated by
transplanting BALB/c BM-TCD and T-regs into BALB/c recipi-
ents, signiﬁcantly greater progenitor colonies were again observed
(p  .01). In summary, donor CD4CD25 T-cells, which are
capable of supporting long-term allogeneic hematopoietic engraft-
ment without inducing GVHD, are able to support splenic day 7
donor progenitors independent of activation by allogeneic antigen
in the recipient and suppression of host resistance. Furthermore,
the independence from T-cell suppression suggests a novel bio-
logical function of this suppressive population. CD4CD25 T-
cells may thus be useful clinically in supporting engraftment fol-
lowing HCT.
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EFFECT OF VERY HIGH CD34 CELL DOSE ON THE OUTCOME OF
ALLOGENEIC HLA IDENTICAL RELATED TRANSPLANTS
Mathews, V., Khoury, H., Vij, R., Adkins, D., DiPersio, J.F., Devine,
S.M. Stem Cell Transplant and Leukemia Program, Washington Uni-
versity, St Louis, MO
We analyzed outcome in a group patients who recieved very high
CD34 cell dose (20  106 CD34 cells/kg)(Group A). We com-
pared this, with a group of patients who recieved between 3-10 
106 CD34 cells/kg (Group B). There was no signiﬁcant difference
between the groups in recipient age, gender, disease risk or reciept
of sex mismatched product. The donor characteristics were also
similar between both groups except for CD34 cell doses which was
30.1  10.2 cells/kg in group A and 6.2  2 cells/kg in group B
(p  0.000001). The dose of CD3, CD4, CD8, CD19 and
CD16/56 subset of cells were also signiﬁcantly higher in group A
than in group B. All but 10 patients in group A recieved a similar
conditioning regimen and all but 5 in group A recieved GVHD
prophylaxis with single agent cyclosporine. Eight patients in group
A recieved alternative ablative conditioning regimens and 2 re-
cieved reduced intensity conditioning regimens. Five patients in
group A also recieved methotrexate for GVHD prophylaxis.
The results of the outcome in the two groups are given in the
table below. Median time to neutrophil (9.4  2.8 vs 10.4  3.3)
and platelet (11.5  4 vs 15.7  13.3) recovery were not signiﬁ-
cantly different in the two groups. There was a trend towards
earlier engraftment in group A compared to group B. While the
risk of grade 2-4 GVHD was not signiﬁcantly different between
the two groups, the risk of severe (grade 3/4) acute GVHD and
deaths attributable to GVHD were signiﬁcantly higher in group A
compared to group B. Incidence of chronic EGVHD was similar in
both groups. There was a trend towards a lower relapse rate in
group A, though the progression free survival and overall survival
in both the groups were similar.
In conclusion infusion of very high doses of CD34 cells in the
setting of a matched related allogeneic stem cell transplanataion is
associated with signiﬁcant increase risk of severe acute GVHD.
Infusion of the entire unmanipulated stem cell product when the
cell dose is 20  106 CD34 cells/kg is not recommended. The
optimal dose remains to be deﬁned.
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EVEN COAGULASE NEGATIVE STAPHYLOCOCCUS INFECTIONS FOL-
LOWING REDUCED INTENSITY TRANSPLANTATION ARE ASSOCIATED
WITH INCREASED TRANSPLANT COMPLICATIONS AND POORER OVER-
ALL SURVIVAL
Chan, G.W.1, Relias, V.1, Klein, A.K.1, Sprague, K.A.1, Foss, F.M.1,
Miller, K.B.2 1. Tufts-New England Medical Center, Boston, MA; 2.
Beth Israel Deaconess Medical Center, Boston, MA
Reduced intensity transplantation (RIT) is associated with
lower transplant related mortality (TRM) but the incidence of
infectious complications remains controversial. We analyzed the
incidence of bacteremia during the ﬁrst 100 days post-trans-
plantation in 106 patients with various malignancies who un-
derwent a reduced intensity regimen of extracorporeal photo-
pheresis  2 cycles, pentostatin 8 mg/m2 by continuous
intravenous infusion over 48 hours, and total body irradiation
600cGy, followed by allogeneic bone marrow stem cell infusion
from a 6/6 HLA matched related donor (n  68), 5/6 HLA
matched related donor (n  8), 6/6 HLA matched unrelated
donor (n  29), or 5/6 HLA matched unrelated donor (n  1).
GVHD prophylaxis consisted of continuous infusion cyclo-
sporin A and short course methotrexate. All patients received
ﬂuoroquinolone prophylaxis until neutrophil engraftment. Dur-
ing the ﬁrst 100 days post-transplantation, grade 2-4 acute
GVHD occurred in 19% of patients, and 56 patients (53%) had
positive blood cultures. Median days to positive cultures were 21
(range 7 to 97). Blood cultures were positive for coagulase
negative staphylococcus (CoNS) (n  36: 63%), other gram-
positive cocci (GPC) (n  10: 10%), gram-negative rods (GNR)
(n5: 9%), fungus (n  3: 5%), gram-positive rods (GPR) (n 
2: 4%), or anaerobes (n  1: 1%). Recurrent infections (same
species 30 days later) occurred in 7 patients (7%), and multiple
infections with different organisms occurred in 16 patients
(15%). Three patients died of sepsis. The incidence of bac-
teremia was higher in patients with grade 2-4 acute GVHD
versus grade 0-1 acute GVHD (70% versus 45%: p  0.05), and
in mismatched related or matched unrelated transplants versus
matched related transplants (66% versus 46%: p  0.05). Bac-
teremia was associated with higher day 100 TRM (26% versus
11%: p  0.06) and lower median overall survival (OS) (9
months versus 35 months: p  0.01). CoNS bacteremia had
similar day 100 TRM as other GPC bacteremia like staphylo-
coccus aureus and enterococcus (22% versus 38%: p  0.37) and
similar day 100 TRM as non-GPC bacteremia (22% versus
30%: p  0.61). There was a trend towards lower median OS in
patients with CoNS bacteremia versus other GPC bacteremia (7
months versus 14 months: p  0.18). In patients undergoing
RIT, CoNS bacteremia, like other bacteremia, was associated
with increased TRM and poorer overall survival. Future studies
on RIT will need to address the issue of bacteremia, especially
CoNS bacteremia.
Table.
CD34
GVHD
2-4
GVHD
3/4
Chronic
EGVHD
Death—
GVHD Relapses
Alive
(2 years)
Group A
(n  31) 45% 22.5% 72% 16% 19% 48%
Group B
(n  96) 50% 8.3% 75% 6.25% 32% 43%
P 0.5 0.0028 0.54 0.0096 0.13 0.47
Table. Bacteremia Following Reduced Intensity Transplantation
Bacteremia
No
Bacteremia P value
Day 100 TRM 26% 11% P  0.06
Median OS 9 months 35 months P  0.01
CoNS
Bacteremia
Other GPC
Bacteremia P value
Day 100 TRM 22% 38% P  0.37
Median OS 7 months 14 months P  0.18
Bacteremia is associated with higher transplant-related mortality and lower overall
survival. Coagulase-negative staphylococcal bacteremia has a similar TRM and OS as
other gram-positive cocci bacteremia.
Oral Presentations
11BB&MT
